Phaseline

Companies › Odyssey Therapeutics

Odyssey Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Other, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OD-07656–Phase 2Ulcerative Colitis (UC)Nov 2026
[14C]OD-001–Phase 1Health VolunteersDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06850727OD-07656Phase 2Ulcerative Colitis (UC)ImmunologyNov 2026
NCT07900607[14C]OD-001Phase 1Health VolunteersOtherDec 2026

From the company's SEC filings

Cash and short-term investments of $326m on 2026-09-30; operating cash outflow about $157m a year; runway about 25 months at that burn, to Oct 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Oruka Therapeutics Mirador Therapeutics Kymera Therapeutics Accro Bioscience (Suzhou) Shattuck Labs

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.